Investorideas.com newswire, news and commentary for leading sectors

Wednesday, February 25, 2015

Solar Stock First Solar (FSLR) Gains Following Earnings Report


Solar Stock First Solar (FSLR) Gains Following Earnings Report


Point Roberts WA, NEW YORK, NY – February 25, 2015 - Investorideas.com, a global news source covering leading sectors including solar stocks issues an alert following First Solar, Inc. (FSLR) yesterday  announcing  financial results for the fourth quarter and year ended December 31, 2014. Net sales were $1,008 million in the quarter, an increase of $119 million from the third quarter of 2014.

Summary:

• Net sales of $1.0 billion for the fourth quarter and $3.4 billion for 2014
• GAAP earnings per fully diluted share of $1.89 for the fourth quarter and $3.91 for 2014
• Cash and marketable securities of $2.0 billion, net cash of $1.8 billion
• 2014 full year bookings of 2.5GWdc; 2015 year-to-date bookings of 311MWdc



First Solar is a leading global provider of comprehensive photovoltaic (PV) solar systems which use its advanced module and system technology. The company's integrated power plant solutions deliver an economically attractive alternative to fossil-fuel electricity generation today. From raw material sourcing through end-of-life module recycling, First Solar's renewable energy systems protect and enhance the environment. For more information about First Solar, please visit www.firstsolar.com.


InvestorIdeas.com newswire is a global recognized news source. We publish original content, third party investment commentary, contributor articles, company news and press releases in leading sectors.
Sectors we cover in include mining, energy, renewable energy, water stocks, food and beverage (including organic and LOHAS, wine), defense and security, biotech, technology and mobile. We have also recently expanded our global coverage to include Latin American stocks, sports and entertainment.

Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas

Sign up for free news alerts at Investorideas.com

Become an Investorideas.com Member and access our online stock directories listing thousands of publicly traded stocks in leading sectors 

Disclaimer/ Disclosure: The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.

Contact Investorideas.com
800 665 0411


Wednesday, February 11, 2015

Follow the Money with Investorideas.com; Biotech Stocks



Follow the Money with Investorideas.com; Biotech Stocks


Point Roberts WA, NEW YORK, NY – February 11, 2015  - Investorideas.com, a global news source covering leading sectors including biotech, medical technology and life sciences stocks updates its biotech stocks directory for investors following the sector. There have been several IPO’s recently and there are an expected 100 IPO’s for the year. Recent additions include (ASND), (ENTL), (FLKS), (ONCE), (TCON) and (ZSAN).


Biotech February 2015 Preview

Aastrom Biosciences, Inc. (NasdaqCM: ASTM) is the leader in developing patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. Aastrom markets two autologous cell therapy products in the United States for the treatment of cartilage repair and skin replacement. Aastrom is also developing MACI(TM), a third-generation autologous chondrocyte implant for the treatment of cartilage defects in the knee, and ixmyelocel-T, a patient-specific multicellular therapy for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy.
ABBOTT LABORATORIES (NYSE: ABT) is a global healthcare company devoted to improving life through the development of products and technologies that span the breadth of healthcare. With a portfolio of leading, science-based offerings in diagnostics, medical devices, nutritionals and branded generic pharmaceuticals, Abbott serves people in more than 150 countries and employs approximately 69,000 people.
Ablynx (Brussels: ABLX.BR) is a biopharmaceutical company engaged in the discovery and development of Nanobodies®, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious and life-threatening human diseases, including inflammation, thrombosis, oncology and pulmonary disease.
Acadia Pharmaceuticals Inc. (NasdaqGS: ACAD) is a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders. ACADIA has a pipeline of product candidates led by pimavanserin, for which we have reported positive Phase III trial results in Parkinson’s disease psychosis and which has the potential to be the first drug approved in the United States for this disorder. We are currently completing NDA-enabling clinical and manufacturing activities for pimavanserin and are planning to submit an NDA with the FDA near the end of 2014. Pimavanserin is also in Phase II development for Alzheimer’s disease psychosis and has successfully completed a Phase II trial in schizophrenia. ACADIA also has clinical-stage programs for chronic pain and glaucoma in collaboration with Allergan, Inc. and two preclinical programs directed at Parkinson’s disease and other neurological disorders. All product candidates are small molecules that emanate from internal discoveries.
Access Pharmaceuticals, Inc. (OTC:ACCP) is an emerging biopharmaceutical company that develops and commercializes proprietary products for the treatment and supportive care of cancer patients. Access developed MuGard and ProctiGard and is developing multiple follow-on products. Access also has other advanced drug delivery technologies including CobaCyte™-mediated targeted delivery and CobOral-oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism.
Acorda Therapeutics, Inc. (NasdaqGS:ACOR) is a biotechnology company focused on developing therapies that improve the lives of people with neurological disorders. Acorda markets three FDA-approved therapies including: AMPYRA (dalfampridine) Extended Release Tablets, 10 mg, a treatment to improve walking in patients with multiple sclerosis (MS); ZANAFLEX CAPSULES® (tizanidine hydrochloride) and Zanaflex tablets, a short-acting drug for the management of spasticity; and QUTENZA® (capsaicin) 8% Patch, for the management of neuropathic pain associated with postherpetic neuralgia. AMPYRA is marketed outside the United States as FAMPYRA® (prolonged-release fampridine tablets) by Biogen Idec under a licensing agreement from Acorda. Acorda has one of the leading pipelines in the industry of novel neurological therapies. The Company is currently developing six clinical-stage therapies and one preclinical stage therapy that address a range of disorders including post-stroke deficits, epilepsy, stroke, peripheral nerve damage, spinal cord injury, neuropathic pain, and heart failure.
Acrux Limited (ASX:ACR.AX) is a dynamic Australian drug delivery business developing and commercialising a range of patient-preferred pharmaceutical products for global markets, using innovative, patented technology to administer drugs through the skin. Fast drying, non-occlusive topical sprays or liquids provide an enhanced transdermal delivery platform with low or no skin irritation, superior cosmetic acceptability, and simple, accurate and flexible dosing.
Active Biotech (Stockholm:ACTI.ST; OTC:ATVBF) a biotechnology company, focuses on developing pharmaceuticals for the treatment of autoimmune/inflammatory diseases and cancer in Sweden. Its projects include Laquinimod, an orally administered compound in Phase III clinical trial development for the treatment of autoimmune diseases, primarily multiple sclerosis; Tasquinimod, which is in Phase III clinical trial for the treatment of prostate cancer; and ANYARA, a protein drug in Phase II/III study for the treatment of renal cell cancer. The company is also developing Paquinimod (57-57), a compound primarily for the treatment of systemic sclerosis; and RhuDex, a compound that is primarily intended to be used as a drug for the treatment of rheumatoid arthritis. Its preclinical project product is ISI (inhibition of S100 interactions) for producing patentable chemical compounds that interact with S100A9, a target molecule for the quinoline compounds.
Addex Therapeutics (Swiss:ADXN.SW; OTC:ADDXF; Berlin:APE.BE) is a discovery and development stage company focused on advancing innovative oral small molecules against rare diseases utilizing its pioneering allosteric modulation-based drug discovery platform. The Company's two lead products are being investigated in Phase 2 clinical testing: dipraglurant (ADX48621, an mGlu5 negative allosteric modulator or NAM) is being developed by Addex to treat Parkinson's disease levodopa-induced dyskinesia (PD-LID) and rare forms of dystonia; and ADX71149 (mGlu2 positive allosteric modulator or PAM) is being developed in collaboration with Janssen Pharmaceuticals, Inc. to treat both schizophrenia and anxiety as seen in patients suffering from major depressive disorder. Addex is also advancing several preclinical programs including: GABA-BR positive allosteric modulator (PAM) for Charcot-Marie-Tooth (type 1a) disease, spasticity in patients with multiple sclerosis (MS), pain, overactive bladder and other disorders; and mGlu4 PAM for MS, Parkinson's disease, anxiety and other diseases. Allosteric modulators are an emerging class of small molecule drugs which have the potential to be more specific and confer significant therapeutic advantages over conventional ‘orthosteric’ small molecule or biological drugs. The Company uses its proprietary discovery platform to target receptors and other proteins that are recognized as essential for the therapeutic modulation of important diseases with unmet medical needs. The Company is currently focused on preserving the value of its assets, including the intellectual property surrounding its portfolio of allosteric modulator drug candidates and its proprietary allosteric modulator technology platform, while pursuing a strategy to secure the resources necessary to advance the pipeline and maximize value for shareholders. In parallel the Company continues to enter collaborations with academic institutions, government organizations and patient groups to advance its portfolio of drug candidates for the benefit of patients.
Adherex Technologies Inc. (OTC:ADHXF) (TSX: AHX.TO) is a clinical-stage biotechnology company developing Sodium Thiosulfate (STS), a chemo-protectant against hearing loss associated with platinum-based chemotherapy. STS is being investigated in two pediatric Phase III studies to evaluate the reduction of ototoxicity and impact on survival.
Admedus Ltd. (ASX:AHZ.AX) is a diversified healthcare company focused on investing in and developing next generation technologies with world class partners, acquiring strategic assets to grow its product and service offerings and expanding revenues from its existing profitable medical sales and distribution business. The Company has assets from research & development through clinical development as well as sales, marketing and distribution. Admedus is in the process of commercialising its innovative tissue engineering technology for regenerative medicine. Admedus also has a major interest in developing the next generation of vaccines with a Brisbane-based research group led by Professor Ian Frazer. The vaccine programmes target disease with significant global potential such as Herpes and Human Papillomavirus.
ADOCIA (Paris:ADOC.PA; OTC:ADOCY) a biotechnology company, develops medicines from therapeutic proteins. The company focuses on insulin therapy and the treatment of diabetic foot ulcer based on its BioChaperone technological platform. Its product pipeline includes BioChaperone PDGF-BB, which has completed Phase II clinical trials for the treatment of diabetic foot ulcer, as well as in pre clinical stage for the treatment of venous ulcer, and bedsores and burns; BioChaperone insulin that is in Phase II clinical trials, as well as in pre clinical stage for the treatment of diabetes; and BioChaperone for monoclonal antibodies, which is in pre clinical stage.
Advanced Cell Technology Inc. (OTC:ACTC) is a Marlborough, Mass.-based biotechnology company focused on the development and commercialization of human embryonic stem cell (hESC) and adult stem cell technology. The company’s most advanced products are in clinical trials for the treatment of dry age-related macular degeneration and Stargardt’s macular degeneration. ACT’s preclinical programs involve cell therapies for the treatment of other ocular disorders and for diseases outside the field of ophthalmology, including autoimmune, inflammatory and wound healing-related disorders. The company’s intellectual property portfolio includes pluripotent stem cell platforms – hESC and induced pluripotent stem cell (iPSC) – and other cell therapy research programs.
Advanced Medical Isotope Corporation (OTC:ADMD) is a late stage development company engaged primarily in the development of brachytherapy devices and medical isotopes for diagnostic and therapeutic applications. AMIC's focus is on transitioning to full operations upon receipt of FDA clearance for its patented brachytherapy cancer products. Brachytherapy uses radiation to destroy cancerous tumors by placing a radioactive isotope inside or next to the treatment area. Annual sales of brachytherapy products exceed $1 billion, about half of which are in the United States. The Company intends to outsource material aspects of manufacturing, distribution, sales and marketing for its products in the United States and to enter into licensing arrangements outside of the United States, though the Company will evaluate its alternatives before finalizing its plans.
Advaxis Inc. (NasdaqCM:ADXS) is a clinical-stage biotechnology company developing multiple cancer immunotherapies based on its proprietary platform intended to redirect the immune system to kill cancer. The Advaxis Lm-LLO technology, using bioengineered live attenuated Listeria monocytogenes bacteria, is the only known cancer immunotherapy agent shown in preclinical studies to both generate cancer fighting T-cells directed against a cancer antigen and neutralize Tregs and MSDCs, that protect the tumor microenvironment from immunologic attack and contribute to tumor growth. Advaxis's lead immunotherapy, ADXS-HPV, targets human papillomavirus (HPV)-associated cancers and is in clinical trials for three indications: Phase 2 in invasive cervical cancer, Phase 1/2 in head and neck cancer, and Phase 1/2 in anal cancer. The FDA has granted Advaxis orphan drug designation for each of these three indications. The Company plans to initiate a registrational clinical program for cervical cancer in 2014 and has established licensing partners in India and Asia for commercialization in those regions. Advaxis is planning to evaluate the combination of ADXS-HPV with an anti-PD-L1 immune checkpoint inhibitor in HPV-associated cancers. Advaxis's second immunotherapy candidate in clinical testing will be ADXS-PSA, which is being developed to address prostate cancer. Advaxis is planning to file an IND with the FDA and initiate a Phase 1-2 clinical study with ADXS-PSA. Advaxis is also developing ADXS-cHER2, to target the Her2 receptor overexpressing cancers. Her2 is overexpressed in certain solid-tumor cancers, including pediatric bone cancer (or osteosarcoma), breast cancer, esophageal, and gastric cancer. Advaxis is developing ADXS-cHER2 for both human and animal-health, and has seen promising results in canine osteosarcoma, which is considered a model for human osteosarcoma. Advaxis is pursuing a clinical program in pediatric osteosarcoma and has licensed ADXS-cHER2 and three other immunotherapy constructs to a major animal-health company. Advaxis is planning to file an IND for ADXS-cHER2 in Her2 overexpressing cancers.
Aeolus Pharmaceuticals, Inc (OTC:AOLS) is developing a new class of broad-spectrum, catalytic-antioxidant compounds that protect healthy tissue from the damaging effects of radiation. Its first compound, AEOL 10150, is being developed, with funding from the U.S. Department of Health and Human Services, as a medical countermeasure against chemical and radiological weapons. Its initial target indications are as a protective agent against the effects of acute radiation syndrome and delayed effects of acute radiation exposure. Aeolus' strategy is to leverage the substantial investment in toxicology, manufacturing and preclinical and clinical studies of AEOL 10150 made by U.S. government agencies, including the contract with BARDA valued, with options, at up to $118.4 million, to efficiently develop the compound for use in oncology.
AEterna Zentaris Inc. (NASDAQCM:AEZS; TSX: AEZ.TO) is a specialty biopharmaceutical company engaged in developing and commercializing novel treatments in oncology and endocrinology. The Company's pipeline encompasses compounds at various stages of development.
Aethlon Medical, Inc. (OTC: AEMD) creates innovative medical devices to address life-threatening diseases. The Aethlon ADAPT™ (Adaptive Dialysis-like Affinity Platform Technology) establishes the basis for a new class of therapeutics that target the rapid elimination of disease enabling particles from the circulatory system of treated patients.  The lead Aethlon ADAPT™ product is the Hemopurifier®, a device that addresses a broad-spectrum of viral pathogens as well as tumor-secreted exosomes that suppress the immune system of cancer patients.  Aethlon is also operating under two government contracts with the Defense Advanced Research Projects Agency (DARPA) related the development of a medical device to reduce the incidence of sepsis. Exosome Sciences, Inc. is a majority owned Aethlon subsidiary that is advancing exosome-based strategies to diagnose and monitor cancer and infectious disease progression. 

Follow the Money with Investorideas.com


Become an Investorideas.com Member and access our online stock directories listing thousands of publicly traded stocks in leading sectors  


InvestorIdeas.com newswire is a global recognized news source. We publish original content, third party investment commentary, contributor articles, company news and press releases in leading sectors.
Sectors we cover in include mining, energy, renewable energy, water stocks, food and beverage (including organic and LOHAS, wine), defense and security, biotech, technology and mobile. We have also recently expanded our global coverage to include Latin American stocks, sports and entertainment.

Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas

Sign up for free news alerts at Investorideas.com
Disclaimer/ Disclosure: The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.
Contact Investorideas.com
800 665 0411


Friday, February 06, 2015

Social Media Stock Earnings Alert; LinkedIn (LNKD) Sets New High on Earnings



Social Media Stock Earnings Alert; LinkedIn (LNKD) Sets New High on Earnings

Point Roberts WA, NEW YORK, NY –February 6,2015 - Investorideas.com, a global news source covering leading sectors including tech stocks reports on social media stock LinkedIn Corporation (LNKD:NYSE). The stock hit a new high of $271.49 following its earning news being digested by investors.



It’s a good day for investors in the social media sector, with Twitter (TWTR) trading at $47.65, up 6.39 (15.49%) as of 10:31AM EST, with a high of $48.8 on its earnings reported at the close yesterday.




LinkedIn Corporation Earnings:
• Revenue for the fourth quarter was $643 million, an increase of 44% compared to $447 million in the fourth quarter of 2013. Revenue in 2014 was $2,219 million, an increase of 45% compared to $1,529 million in 2013.

• Net income attributable to common stockholders for the fourth quarter was $3 million, compared to net income of $4 million for the fourth quarter of 2013. Non-GAAP net income for the fourth quarter was $77 million, compared to $48 million for the fourth quarter of 2013. Net loss attributable to common stockholders in 2014 was ($16) million, compared to net income of $27 million in 2013. Non-GAAP net income in 2014 was $254 million, compared to $192 million in 2013. Non-GAAP net income excludes tax affected non-cash items, such as stock-based compensation and amortization of acquired intangible assets. For additional information, see section "Non-GAAP Financial Measures."

• Adjusted EBITDA for the fourth quarter was $179 million, or 28% of revenue, compared to $111 million for the fourth quarter of 2013, or 25% of revenue. Adjusted EBITDA in 2014 was $592 million, or 27% of revenue, compared to $376 million in 2013, or 25% of revenue.

• GAAP diluted EPS for the fourth quarter was $0.02, compared to GAAP diluted EPS of $0.03 for the fourth quarter 2013; non-GAAP diluted EPS for the fourth quarter was $0.61, compared to non-GAAP diluted EPS of $0.39 for the fourth quarter of 2013. GAAP diluted EPS in 2014 was ($0.13), compared to GAAP diluted EPS of $0.23 in 2013; non-GAAP diluted EPS in 2014 was $2.02, compared to non-GAAP diluted EPS of $1.61 in 2013.

"The fourth quarter capped another successful year for LinkedIn, which was marked by steady member growth and strong financial results," said Jeff Weiner, CEO of LinkedIn. "We continued to make significant progress against a number of multi-year, strategic initiatives including mobile, jobs, content, and global expansion."

Fourth Quarter Operating Summary
• Talent Solutions: Revenue from Talent Solutions products totaled $369 million, an increase of 41% compared to the fourth quarter of 2013. Talent Solutions revenue represented 57% of total revenue in the fourth quarter of 2014, compared to 58% of total revenue in the fourth quarter of 2013.

• Marketing Solutions: Revenue from Marketing Solutions products totaled $153 million, an increase of 56% compared to the fourth quarter of 2013. Marketing Solutions revenue represented 24% of total revenue in the fourth quarter of 2014, compared to 22% of total revenue in the fourth quarter of 2013.

• Premium Subscriptions: Revenue from Premium Subscriptions products totaled $121 million, an increase of 38% compared to the fourth quarter of 2013. Premium Subscriptions represented 19% of total revenue in the fourth quarter of 2014, compared to 20% of total revenue in the fourth quarter of 2013.

Revenue from the U.S. totaled $388 million, and represented 60% of total revenue in the fourth quarter of 2014. Revenue from international markets totaled $255 million, and represented 40% of total revenue in the fourth quarter of 2014.

Revenue from the field sales channel totaled $414 million, and represented 64% of total revenue in the fourth quarter of 2014. Revenue from the online channel totaled $230 million, and represented 36% of total revenue in the fourth quarter of 2014.

2014 Highlights and Strategic Announcements
Throughout 2014, LinkedIn:
• Increased the scale and relevance of job listings through the acquisition of Bright. LinkedIn now has 3 million active job listings on the platform, an approximate 10x increase versus last year. As we continue to add jobs on LinkedIn, we grow closer to realizing our vision of having every job in the world on LinkedIn.

• Expanded the professional publishing platform by introducing long-form posting to more than 230 million English-speaking members. Members are increasingly creating content on LinkedIn, and we recently surpassed one million total long-form posts and 50,000 posts per week. Through the publishing platform, Pulse, and SlideShare, we seek to make the world's professional knowledge available on LinkedIn.

• Broadened its global reach, with nearly 70% of total members coming from non-U.S. geographies. In February, we launched a localized version of LinkedIn in Simplified Chinese & Traditional Chinese. Since launch, LinkedIn has nearly doubled its Chinese member base from 4 million to more than 8 million. More recently, LinkedIn's application for an ICP license in China for the local Chinese LinkedIn site was approved, better enabling us to connect the world's professionals.

"The fourth quarter underscored a strong 2014 for LinkedIn, as we demonstrated growing organic engagement and solid performance across our three, diverse product lines." said Steve Sordello, CFO of LinkedIn. "Entering 2015, we plan to continue investing in our long-term roadmap to further pursue our vision to build the world's first economic graph."

Business Outlook
LinkedIn is providing guidance for the first quarter and full year of 2015:
• Q1 2015 Guidance: Revenue is expected to range between $618 million and $622 million. Adjusted EBITDA is expected to range between $152 million and $154 million. Non-GAAP EPS is expected to be approximately $0.53. The company expects depreciation of approximately $61 million, amortization of approximately $12 million, stock-based compensation of approximately $103 million, and 128 million fully-diluted weighted shares.

• Full Year 2015 Guidance: Revenue is expected to range between $2.93 billion and $2.95 billion. Adjusted EBITDA is expected to be approximately $785 million. Non-GAAP EPS is expected to be approximately $2.95. The company expects depreciation of approximately $270 million, amortization of approximately $45 million, stock-based compensation of approximately $460 million, and approximately 130 million fully-diluted weighted shares.

InvestorIdeas.com newswire is a global recognized news source. We publish original content, third party investment commentary, contributor articles, company news and press releases in leading sectors.
Sectors we cover in include mining, energy, renewable energy, water stocks, food and beverage (including organic and LOHAS, wine), defense and security, biotech, technology and mobile. We have also recently expanded our global coverage to include Latin American stocks, sports and entertainment.

Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas

Sign up for free news alerts at Investorideas.com

Become an Investorideas.com Member and access our online stock directories listing thousands of publicly traded stocks in leading sectors 

Disclaimer/ Disclosure: The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.

Contact Investorideas.com
800 665 0411


Tech Stock Earnings Alert; Twitter (TWTR) Reports Fourth Quarter and Fiscal Year 2014 Results



Tech Stock Earnings Alert; Twitter (TWTR) Reports Fourth Quarter and Fiscal Year 2014 Results

Point Roberts WA, NEW YORK, NY – February 6, 2015 - Investorideas.com, a global news source covering leading sectors including tech stocks reports on social media stock Twitter  (NYSE: TWTR) .

One the market close February 5th, Twitter, Inc. (NYSE: TWTR) reported financial results for the quarter and fiscal year ended December 31, 2014. The stock traded up over 9% in after-hours trading following the news.
Highlights -
  • Q4 revenue of $479 million, up 97% year-over-year
  • Q4 net loss of $125 million and non-GAAP net income of $79 million
  • Q4 GAAP EPS of ($0.20) and non-GAAP EPS of $0.12
  • Q4 adjusted EBITDA of $141 million, representing an adjusted EBITDA margin of 30%
  • 2014 revenue of $1,403 million, up 111% year-over-year
  • 2014 net loss of $578 million and non-GAAP net income of $101 million
  • 2014 GAAP EPS of ($0.96) and non-GAAP EPS of $0.14
  • 2014 adjusted EBITDA of $301 million, representing an adjusted EBITDA margin of 21%
"We closed out the year with our business advancing at a great pace. Revenue growth accelerated again for the full year, and we had record quarterly profits on an adjusted EBITDA basis," said Dick Costolo, CEO of Twitter. "In addition, the trend thus far in Q1 leads us to believe that the absolute number of net users added in Q1 will be similar to what we saw during the first three quarters of 2014."

For information regarding the non-GAAP financial measures discussed in this release, please see "Non-GAAP Financial Measures" and "Reconciliation of GAAP to Non-GAAP Financial Measures" below.
Fourth Quarter 2014 Operational Highlights
  • Average Monthly Active Users (MAUs) were 288 million for the fourth quarter, an increase of 20% year-over-year, which reflects a loss of approximately 4 million net Monthly Active Users in the fourth quarter due to changes in third party integrations.
  • Average Mobile MAUs represented approximately 80% of total MAUs.
  • Timeline views reached 182 billion for the fourth quarter of 2014, an increase of 23% year-over-year.
  • Advertising revenue per thousand timeline views reached $2.37 in the fourth quarter of 2014, an increase of 60% year-over-year.
Fourth Quarter 2014 Product Highlights
  • Users: Twitter launched the ability for people to share a Tweet privately through a Direct Message, making it easier for people to have private discussions around public content. Twitter also launched the Audio Card, which lets people discover and listen to audio directly in their timeline on Android and iOS devices.
  • Advertisers: Twitter began testing Twitter Offers in the United States, enabling advertisers to create credit card-linked promotions and share them directly with people on Twitter. Twitter also launched tailored audiences for mobile apps, a new way for advertisers to create targetable audience segments based on mobile app actions such as installs, purchases, or sign-ups. Finally, Twitter launched two new mobile targeting options including the ability to target by mobile carrier and the ability to target users with new mobile devices.
  • International Expansion: Twitter continued the international expansion of advertising offerings to 13 additional markets worldwide. Twitter's self serve ad products expanded to 8 new markets in Q4 and now serve marketers in 28 countries.
  • Developers: Twitter held its first mobile developer conference, Flight, where it unveiled Fabric, a single modular Software Developer Kit consisting of app stability and analytics tools through Crashlytics, monetization offerings through MoPub, identity and sign-in services through Twitter and a first-of-its-kind offering called Digits, and content distribution and syndication through an improved Twitter SDK.
  • January Launches: In January, Twitter launched a recap feature, marked with a "While you were away" heading, that surfaces at the top of the Timeline some of the best Tweets people may have missed from accounts people follow; group Direct Messaging, which lets people expand private conversations from one other participant to as many as 20, and new video functionality that allows people to capture, edit and share videos right from within the Twitter app.
Fourth Quarter 2014 Financial Highlights
Revenue - Revenue for the fourth quarter of 2014 totaled $479 million, an increase of 97% compared to $243 million in the same period in 2013.
  • Advertising revenue totaled $432 million, an increase of 97% year-over-year.
  • Mobile advertising revenue was 88% of total advertising revenue.
  • Data licensing and other revenue totaled $47 million, an increase of 105% year-over-year.
  • International revenue totaled $164 million, an increase of 149% year-over-year.
  • International revenue was 34% of total revenue.
Net loss - GAAP net loss was $125 million for the fourth quarter of 2014 compared to a GAAP net loss of $511 million in the same period in 2013. GAAP net loss for the fourth quarter of 2014 included $177 million of stock-based compensation expense.
Adjusted EBITDA - Adjusted EBITDA was $141 million for the fourth quarter of 2014, an increase of 216% compared to $45 million in the same period in 2013.
Non-GAAP net income - Non-GAAP net income was $79 million for the fourth quarter of 2014, an increase of 712% compared to $10 million in the same period in 2013.
EPS - Basic and diluted GAAP EPS was ($0.20) for the fourth quarter of 2014 compared to ($1.41) in the same period in 2013.
Non-GAAP EPS - Non-GAAP EPS was $0.12 for the fourth quarter of 2014 compared to $0.02 in the same period in 2013.
Capital expenditures - Purchases of property and equipment for the fourth quarter of 2014 were $69 million. Additionally, $30 million of equipment was financed through capital leases during the fourth quarter of 2014.
Cash, cash equivalents and marketable securities - As of December 31, 2014, cash, cash equivalents, and marketable securities were approximately $3.6 billion, compared to $3.6 billion as of September 30, 2014.
Outlook
Twitter's outlook for the first quarter of 2015 is as follows:
  • Revenue is projected to be in the range of $440 million to $450 million.
  • Adjusted EBITDA is projected to be in the range of $89 million to $94 million.
  • Stock-based compensation expense is projected to be in the range of $160 million to $170 million, excluding the impact of equity awards that may be granted in connection with potential future acquisitions.
Twitter's outlook for the full year of 2015 is as follows:
  • Revenue is projected to be in the range of $2.3 billion to $2.35 billion.
  • Adjusted EBITDA is projected to be in the range of $550 million to $575 million.
  • Capital expenditures are projected to be in the range of $500 million to $650 million.
  • Stock-based compensation expense is projected to be in the range of $700 million to $750 million, excluding the impact of equity awards that may be granted in connection with potential future acquisitions.
Note that Twitter's outlook for the first quarter and full year of 2015 reflects foreign exchange rates as of January 31, 2015.

Webcast and Conference Call Details
Twitter will host a conference call today, Thursday, February 5, 2015, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to discuss financial results. Questions submitted via Twitter, directed to @TwitterIR, using the hashtag #TWTRearnings will be considered during the Q&A portion of the conference call in addition to questions submitted by conference call participants. A live webcast of the conference call, Twitter's financial results and supplemental slides will be accessible from the Investor Relations page of Twitter's website at investor.twitterinc.com. A replay will be archived and accessible at the same website after the conference call. Twitter has used, and intends to continue to use, its Investor Relations website (investor.twitterinc.com), as well as certain Twitter accounts (@dickc, @twitter and @twitterIR), as means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.

About Twitter, Inc.
Twitter (NYSE: TWTR) is a global platform for public self-expression and conversation in real time. By developing a fundamentally new way for people to create, distribute and discover content, we have democratized content creation and distribution, enabling any voice to echo around the world instantly and unfiltered. The service can be accessed at Twitter.com, via the Twitter mobile application and via text message. Available in more than 35 languages, Twitter has 288 million monthly active users. For more information, visit discover.twitter.com or follow @twitter.


InvestorIdeas.com newswire is a global recognized news source. We publish original content, third party investment commentary, contributor articles, company news and press releases in leading sectors.
Sectors we cover in include mining, energy, renewable energy, water stocks, food and beverage (including organic and LOHAS, wine), defense and security, biotech, technology and mobile. We have also recently expanded our global coverage to include Latin American stocks, sports and entertainment.

Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas

Sign up for free news alerts at Investorideas.com

Become an Investorideas.com Member and access our online stock directories listing thousands of publicly traded stocks in leading sectors 

Disclaimer/ Disclosure: The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.

Contact Investorideas.com
800 665 0411


Wednesday, February 04, 2015

Westport Innovations (TSX:WPT/NASDAQ:WPRT) Gains on EPA Certification News

Westport Innovations (TSX:WPT/NASDAQ:WPRT) Gains on EPA Certification News

Point Roberts WA, NEW YORK, NY – February 4,2015 - Investorideas.com, a global news source covering leading sectors including natural gas and cleantech stocks reports on natural gas engine company, Westport Innovations Inc. (TSX:WPT / NASDAQ:WPRT), (WPRT) is trading at $4.16 up 0.49(13.35%) as of  2:22PM EST, with a day high of $4.47.

The stock moved on news it has received certification from the Environmental Protection Agency (EPA) for its 2015 Ford Transit Van. As Ford's largest qualified vehicle modifier (QVM), Westport is offering the 2015 Ford Transit Van as a dedicated compressed natural gas (CNG) Westport WiNG™ Power System vehicle. Westport expects California Air Resources Board (CARB) certification in early 2015.




About Westport
Westport engineers the world's most advanced natural gas engines and vehicles. More than that, we are fundamentally changing the way the world travels the roads, rails and seas. We work with original equipment manufacturers (OEMs) worldwide from design through to production, creating products to meet the growing demand for vehicle technology that will reduce both emissions and fuel costs. To learn more about our business, visit westport.com, subscribe to our RSS feed, or follow us on Twitter @WestportDotCom.

InvestorIdeas.com newswire is a global recognized news source. We publish original content, third party investment commentary, contributor articles, company news and press releases in leading sectors.
Sectors we cover in include mining, energy, renewable energy, water stocks, food and beverage (including organic and LOHAS, wine), defense and security, biotech, technology and mobile. We have also recently expanded our global coverage to include Latin American stocks, sports and entertainment.

Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas

Sign up for free news alerts at Investorideas.com

Become an Investorideas.com Member and access our online stock directories listing thousands of publicly traded stocks in leading sectors  

Disclaimer/ Disclosure: The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.

Contact Investorideas.com
800 665 0411


InvestorIdeas.com Newswire